ASND
ASND clinical trials: Ascendis Pharma A/S
Every trial on ClinicalTrials.gov where Ascendis Pharma A/S is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 17
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ASND on the catalyst calendar · ASND registry changes
- Primary completion Sep 2028Sponsor estimatePhase 3NCT07924059Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in AchondroplasiaAscendis Pharma A/S · AchondroplasiaNot yet recruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 3NCT07221851Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With...Ascendis Pharma A/S · Turner SyndromeRecruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 3NCT07917143A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With HypochondroplasiaAscendis Pharma A/S · HypochondroplasiaNot yet recruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2NCT06732895A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Ascendis Pharma A/S · AchondroplasiaActive, not recruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimateNo phase registeredNCT07264634A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)Ascendis Pharma A/S · HypoparathyroidismRecruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 3NCT07706764A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismAscendis Pharma A/S · HypoparathyroidismRecruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 27, 2022ActualPhase 2NCT04085523A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal...Ascendis Pharma A/S · AchondroplasiaCompletedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2023ActualPhase 3NCT03344458A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a...Ascendis Pharma A/S · Growth Hormone Deficiency, PediatricCompletedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2015ActualPhase 2NCT01947907Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone...Ascendis Pharma A/S · Growth Hormone Deficiency (GHD)CompletedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2011ActualPhase 2NCT01247675A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone DeficiencyAscendis Pharma A/S · Adult Growth Hormone DeficiencyCompletedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2020ActualPhase 2NCT04009291A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismAscendis Pharma A/S · HypoparathyroidismCompletedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT06079398A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaAscendis Pharma A/S · AchondroplasiaRecruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2036Sponsor estimateNo phase registeredNCT07345494A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During...Ascendis Pharma A/S · HypoparathyroidismRecruitingASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2025ActualPhase 2NCT05980598TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaAscendis Pharma A/S · Head and Neck NeoplasmsTerminatedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2024ActualNo phase registeredNCT03875534A Multi-center, Longitudinal, Observational Study of Children With AchondroplasiaAscendis Pharma A/S · AchondroplasiaCompletedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2015ActualPhase 1NCT03803163A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male VolunteersAscendis Pharma A/S · Healthy VolunteersTerminatedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2010ActualPhase 1NCT01010425Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)Ascendis Pharma A/S · HealthyCompletedASNDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2022Sponsor estimatePhase 3NCT04326374Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone DeficiencyVisen Pharmaceuticals (Shanghai) Co., Ltd. · Growth Hormone DeficiencyUnknown statusASNDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner